AbbVie’s telisotuzumab adizutecan achieved an ORR of 63% in EGFR-mutant NSCLC patients, with current ADC options in this ...

The MHRA has approved aumolertinib for adult patients with non-small cell lung cancer (NSCLC), following a groundbreaking ...

While the approval is a historic event for the BiTE drug class in solid tumours, the market share opportunity is restricted ...

COCOON dermatologic management lessened skin side effects and improved quality of life versus standard care for patients with ...

Helena Yu, MD, discusses the importance of zipalertinib's oral administration route for patients with EGFRm non–small cell lung cancer.

Chemoimmunotherapy offers greater benefits than harms as first-line treatment for older patients with NSCLC, data suggest.

This priority review designation for sevabertinib in previously treated HER2-mutant non–small cell lung cancer is supported ...

Despite its success in advanced melanoma, Bristol Myers Squibb’s fixed-dose PD-1/LAG-3 combo, Opdualag, failed to move the ...

BMS will co-develop and co-commercialize BioNTech’s bispecific antibody BNT327 for solid tumors in a deal worth up to $11.1B ...

The leading PD-1+ NSCLC Companies such as Arcus Biosciences, Akeso Biopharma, Biotheus, GlaxoSmithKline, AstraZeneca, Pfizer, Shandong Boan Biotechnology, Genor Biopharma and others. Promising PD-1+ ...